Remove 2018 Remove Hospital Remove Nuclear Medicine Remove PET Scan
article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Lutathera was approved for adults by the FDA in 2018 after the therapy resulted in progression-free survival (median overall survival of 11.7

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Lutathera was approved for adults by the FDA in 2018 after the therapy resulted in progression-free survival (median overall survival of 11.7

article thumbnail

GE HealthCare Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI

Imaging Technology

Flavio Forrer , MD, PhD, Chairman of Nuclear Medicine in the Division of Radiology and Nuclear Medicine at Kantonsspital St. Measurement follows NEMA NU 2-2018. [v] v] Up to 53% reduction of PET scan time on Omni Legend 32 cm compared to Discovery MI 25 cm, as demonstrated in phantom testing. [vi]